Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Cholesterol-lowering medications were associated with at least a 40% reduction in mortality.
The company has been besieged with lawsuits from people who claim that the product caused their cancer.
Women with gynecologic cancer who watched these classic films during cancer treatment saw an improvement in their emotional well-being.
The PARP inhibitor delayed disease progression by 20 months compared with a placebo.
Zejula delayed disease progression in people with advanced ovarian cancer who had a complete or partial response to platinum chemotherapy.
This is your opportunity to benefit gynecologic cancer research and join survivors, oncologists, and advocates from all over the country.
It’s possible to identify these individuals in advance, helping them to focus on clinical trials of more effective treatments.
Cancer Health spoke with the Foundation for Women’s Cancer about gynecologic cancer education, prevention and eradication.
The study isn’t conclusive, but if there is an increased risk, it’s likely to be very small.
When you ask patients what’s most important to them, they want to know what’s going to help them live longer overall.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.